Optimized antibodies that target CD19

The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg³R or alters effector function as compared to the parent antibody. Also disclosed are methods of us...

Full description

Saved in:
Bibliographic Details
Main Authors Bernett, Matthew J, Richards, John O, Zhukovsky, Eugene Alexander, Lazar, Gregory Alan, Karki, Sher Bahadur, Pong, Erik WeiKing, Desjarlais, John R, Chu, Seung Yup
Format Patent
LanguageEnglish
French
German
Published 22.03.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

Abstract The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg³R or alters effector function as compared to the parent antibody. Also disclosed are methods of using said antibodies.
AbstractList The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg³R or alters effector function as compared to the parent antibody. Also disclosed are methods of using said antibodies.
Author Pong, Erik WeiKing
Richards, John O
Desjarlais, John R
Lazar, Gregory Alan
Karki, Sher Bahadur
Zhukovsky, Eugene Alexander
Bernett, Matthew J
Chu, Seung Yup
Author_xml – fullname: Bernett, Matthew J
– fullname: Richards, John O
– fullname: Zhukovsky, Eugene Alexander
– fullname: Lazar, Gregory Alan
– fullname: Karki, Sher Bahadur
– fullname: Pong, Erik WeiKing
– fullname: Desjarlais, John R
– fullname: Chu, Seung Yup
BookMark eNrjYmDJy89L5WRQ9S8oyczNrEpNUUjMK8lMyk_JTC1WKMlILFEoSSxKTy1RcHYxtORhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAUbGFsZGluZOFsZEKAEAp3MoBg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate Auf CD19 gerichtete optimierte Antikörper
Anticorps optimisés ciblant le CD19
ExternalDocumentID EP2383297B8
GroupedDBID EVB
ID FETCH-epo_espacenet_EP2383297B83
IEDL.DBID EVB
IngestDate Fri Jul 19 13:59:54 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP2383297B83
Notes Application Number: EP20110173336
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230322&DB=EPODOC&CC=EP&NR=2383297B8
ParticipantIDs epo_espacenet_EP2383297B8
PublicationCentury 2000
PublicationDate 20230322
PublicationDateYYYYMMDD 2023-03-22
PublicationDate_xml – month: 03
  year: 2023
  text: 20230322
  day: 22
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies Xencor, Inc
RelatedCompanies_xml – name: Xencor, Inc
Score 3.4636757
Snippet The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein...
SourceID epo
SourceType Open Access Repository
SubjectTerms BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Title Optimized antibodies that target CD19
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230322&DB=EPODOC&locale=&CC=EP&NR=2383297B8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS8MwFH_MKepNp-L8ogftrdjPtTkUoV8MYWuRKbuNpklZD27DRQT_el9iN73oLSTwkjzyy3sv-eUF4NZlLHA4Asl2mGm4lHsGlcwcr2I1GZSOX6oEpqPxYPjsPk69aQeazVsYlSf0QyVHRERViHeh9uvVzyFWoriV63vaYNXyIZuEid5Gx-hP4wLVkyhMizzJYz2OsaSPn0K0TI5N_CjYgV3pRcs0--lLJB-lrH5blOwI9goUthDH0OGLHhzEm4_XerA_au-7sdhCb30CdzmC-7X55ExDZTR0Kel_mpiXQvtmc2txYpFT0LJ0Eg8N7G-2ndssLbYjc86giyE_P5d8I4uWGIzVxAxcXnmkrC2HEZ-gs4QuhdmH_p9iLv5pu4RDqSTJobLtK-iKt3d-jUZV0Bulji_y-HoE
link.rule.ids 230,309,786,891,25594,76903
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3JTsMwEB2Vgig3KKCWNQfILSJrEx8ipGwK0CxCAfUWZXFEDrQVDULi65mYtHCBm2VLXkZ5nnnO8xjgSi1LQ6EIJFkpRUHNqSbkrTJHK8qKTDJFz1gC0yCc-E_q_Uyb9aBe34VheUI_WHJERFSBeG_Yfr38OcRymLZydZPXWLW49RLT4Tt2jPE0fqC8Y5luHDmRzds2lvjw0UTPpMhEt4wt2NaRETKm9Gy1l1KWvz2Ktw87MXY2bw6gR-dDGNjrh9eGsBt0_7ux2EFvdQjXEYL7tf6kJYfGqPNFK__jmpes4b7V3JztSOQIOM9NbF_A8dLN2lI33sxMOYY-Un46avVGUp4hGauIaKi00EhWSUpJdILBEoYU4hjGf3Zz8k_bJQz8JJim07vw4RT2WoO1eipZPoN-8_ZOz9HBNvkFM80XzHZ87g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Optimized+antibodies+that+target+CD19&rft.inventor=Bernett%2C+Matthew+J&rft.inventor=Richards%2C+John+O&rft.inventor=Zhukovsky%2C+Eugene+Alexander&rft.inventor=Lazar%2C+Gregory+Alan&rft.inventor=Karki%2C+Sher+Bahadur&rft.inventor=Pong%2C+Erik+WeiKing&rft.inventor=Desjarlais%2C+John+R&rft.inventor=Chu%2C+Seung+Yup&rft.date=2023-03-22&rft.externalDBID=B8&rft.externalDocID=EP2383297B8